Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF for Glioblastoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
GlioblastomaAutologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF - Biological
Eligibility
18 - 90
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at whether it's possible to generate an investigational vaccine for patients with brain cancer who have already started chemotherapy.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Leukapheresis to investigational product release date or up to 6 weeks

Week 6
Ability to generate CMV pp65 RNA-pulsed DCs in patients receiving adjuvant temozolomide chemotherapy after radiotherapy.

Trial Safety

Trial Design

1 Treatment Group

Autologous DCs derived from PBMC loaded with RNA
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF · No Placebo Group · Phase 1

Autologous DCs derived from PBMC loaded with RNA
Biological
Experimental Group · 1 Intervention: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: leukapheresis to investigational product release date or up to 6 weeks

Who is running the clinical trial?

Immunomic Therapeutics, Inc.Industry Sponsor
8 Previous Clinical Trials
472 Total Patients Enrolled
2 Trials studying Glioblastoma
185 Patients Enrolled for Glioblastoma
University of FloridaLead Sponsor
1,251 Previous Clinical Trials
698,803 Total Patients Enrolled
10 Trials studying Glioblastoma
468 Patients Enrolled for Glioblastoma
Ashley Ghiaseddin, MDPrincipal InvestigatorUniversity of Florida
2 Previous Clinical Trials
49 Total Patients Enrolled
2 Trials studying Glioblastoma
49 Patients Enrolled for Glioblastoma

Eligibility Criteria

Age 18 - 90 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: